SG10201710475WA - Preparing antibodies from cho cell cultures for conjugation - Google Patents
Preparing antibodies from cho cell cultures for conjugationInfo
- Publication number
- SG10201710475WA SG10201710475WA SG10201710475WA SG10201710475WA SG10201710475WA SG 10201710475W A SG10201710475W A SG 10201710475WA SG 10201710475W A SG10201710475W A SG 10201710475WA SG 10201710475W A SG10201710475W A SG 10201710475WA SG 10201710475W A SG10201710475W A SG 10201710475WA
- Authority
- SG
- Singapore
- Prior art keywords
- conjugation
- cell cultures
- cho cell
- preparing antibodies
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
- C12Y108/03—Oxidoreductases acting on sulfur groups as donors (1.8) with oxygen as acceptor (1.8.3)
- C12Y108/03002—Thiol oxidase (1.8.3.2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Water Supply & Treatment (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361908568P | 2013-11-25 | 2013-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201710475WA true SG10201710475WA (en) | 2018-01-30 |
Family
ID=53180202
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201710475WA SG10201710475WA (en) | 2013-11-25 | 2014-11-21 | Preparing antibodies from cho cell cultures for conjugation |
SG11201602995VA SG11201602995VA (en) | 2013-11-25 | 2014-11-21 | Preparing antibodies from cho cell cultures for conjugation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201602995VA SG11201602995VA (en) | 2013-11-25 | 2014-11-21 | Preparing antibodies from cho cell cultures for conjugation |
Country Status (14)
Country | Link |
---|---|
US (2) | US10457976B2 (en) |
EP (1) | EP3074036B1 (en) |
JP (2) | JP6529188B2 (en) |
KR (1) | KR102306493B1 (en) |
CN (1) | CN105979963B (en) |
AU (1) | AU2014352824B2 (en) |
CA (1) | CA2928238C (en) |
DK (1) | DK3074036T3 (en) |
EA (1) | EA034123B1 (en) |
ES (1) | ES2753269T3 (en) |
IL (1) | IL245190B (en) |
MX (1) | MX2016006551A (en) |
SG (2) | SG10201710475WA (en) |
WO (1) | WO2015077605A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150083689A (en) * | 2014-01-10 | 2015-07-20 | 삼성전자주식회사 | Method of Purification of anti-c-Met antibody |
JPWO2016121701A1 (en) | 2015-01-26 | 2017-11-09 | 株式会社カネカ | Affinity separation matrix for protein purification containing immunoglobulin κ chain variable region |
WO2016121703A1 (en) | 2015-01-26 | 2016-08-04 | 株式会社カネカ | MUTANT IMMUNOGLOBULIN κ CHAIN VARIABLE REGION-BINDING PEPTIDE |
EP3394082B1 (en) * | 2015-12-21 | 2020-08-12 | Pfizer Inc | Purification of antibody drug conjugates using a sodium phosphate gradient |
WO2017195638A1 (en) * | 2016-05-09 | 2017-11-16 | 株式会社カネカ | Method for refining antibody or antibody fragment containing κ-chain variable region |
WO2018116269A1 (en) * | 2016-12-22 | 2018-06-28 | Lupin Limited | Depth filtration of a protein |
BR112021021972A2 (en) * | 2019-05-03 | 2021-12-21 | Hoffmann La Roche | Methods of reducing a rate of enzymatic hydrolysis activity, of reducing the level of one or more hydrolytic enzymes, and of reducing the degradation of a polysorbate, pharmaceutical compositions, and formulated antibody moiety compositions |
WO2021024133A2 (en) | 2019-08-06 | 2021-02-11 | Glaxosmithkline Intellectual Property Development Limited | Biopharmacuetical compositions and related methods |
CN117794954A (en) | 2021-08-03 | 2024-03-29 | 葛兰素史密斯克莱知识产权发展有限公司 | Biopharmaceutical composition and method for labeling peptide profile with stable isotope |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
EP0871490B1 (en) | 1995-12-22 | 2003-03-19 | Bristol-Myers Squibb Company | Branched hydrazone linkers |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
ES2556641T3 (en) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Drug conjugates and their use to treat cancer, an autoimmune disease or an infectious disease |
KR101438983B1 (en) | 2003-11-06 | 2014-09-05 | 시애틀 지네틱스, 인크. | Monomethylvaline compounds capable of conjugation to ligands |
US8029783B2 (en) * | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
WO2007109163A2 (en) * | 2006-03-16 | 2007-09-27 | Amgen Inc | Wash buffer and method of using |
ES2666170T3 (en) | 2007-10-30 | 2018-05-03 | Genentech, Inc. | Purification of antibodies by cation exchange chromatography |
KR101238061B1 (en) | 2009-03-31 | 2013-02-27 | 한화케미칼 주식회사 | Human monoclonal antibody that specifically binds to VCAM-1 and a composition for treating an inflammatory disease or a cancer comprising the same |
BR112012026801B8 (en) | 2010-04-15 | 2021-05-25 | Medimmune Ltd | targeted pyrrolobenzodiazepine conjugates, pharmaceutical composition, use thereof for treatment of a proliferative or autoimmune disease and drug binding |
ES2691931T3 (en) * | 2012-03-07 | 2018-11-29 | Yeda Research And Development Co. Ltd. | Compositions for inhibition of quiescin sulfhydryl oxidase (QSOX1) and uses thereof |
US20130309223A1 (en) * | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
-
2014
- 2014-11-21 ES ES14863650T patent/ES2753269T3/en active Active
- 2014-11-21 SG SG10201710475WA patent/SG10201710475WA/en unknown
- 2014-11-21 KR KR1020167016632A patent/KR102306493B1/en active IP Right Grant
- 2014-11-21 EP EP14863650.9A patent/EP3074036B1/en active Active
- 2014-11-21 DK DK14863650T patent/DK3074036T3/en active
- 2014-11-21 WO PCT/US2014/066889 patent/WO2015077605A1/en active Application Filing
- 2014-11-21 EA EA201691094A patent/EA034123B1/en unknown
- 2014-11-21 US US15/039,179 patent/US10457976B2/en active Active
- 2014-11-21 AU AU2014352824A patent/AU2014352824B2/en active Active
- 2014-11-21 SG SG11201602995VA patent/SG11201602995VA/en unknown
- 2014-11-21 MX MX2016006551A patent/MX2016006551A/en unknown
- 2014-11-21 JP JP2016533645A patent/JP6529188B2/en active Active
- 2014-11-21 CA CA2928238A patent/CA2928238C/en active Active
- 2014-11-21 CN CN201480064191.6A patent/CN105979963B/en active Active
-
2016
- 2016-04-19 IL IL245190A patent/IL245190B/en active IP Right Grant
-
2018
- 2018-12-26 JP JP2018242033A patent/JP2019048888A/en active Pending
-
2019
- 2019-09-17 US US16/573,154 patent/US20200063180A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2928238A1 (en) | 2015-05-28 |
AU2014352824A1 (en) | 2016-05-12 |
EA034123B1 (en) | 2019-12-30 |
SG11201602995VA (en) | 2016-05-30 |
US10457976B2 (en) | 2019-10-29 |
EA201691094A1 (en) | 2016-09-30 |
IL245190B (en) | 2021-02-28 |
AU2014352824B2 (en) | 2019-07-18 |
ES2753269T3 (en) | 2020-04-07 |
CN105979963B (en) | 2020-03-03 |
EP3074036B1 (en) | 2019-09-18 |
IL245190A0 (en) | 2016-06-30 |
MX2016006551A (en) | 2016-09-06 |
JP2016539130A (en) | 2016-12-15 |
EP3074036A4 (en) | 2017-07-26 |
KR20160089454A (en) | 2016-07-27 |
WO2015077605A1 (en) | 2015-05-28 |
EP3074036A1 (en) | 2016-10-05 |
JP2019048888A (en) | 2019-03-28 |
US20200063180A1 (en) | 2020-02-27 |
CN105979963A (en) | 2016-09-28 |
DK3074036T3 (en) | 2019-11-18 |
KR102306493B1 (en) | 2021-09-28 |
CA2928238C (en) | 2021-08-17 |
JP6529188B2 (en) | 2019-06-12 |
US20170159099A1 (en) | 2017-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL264558A (en) | Anti-il-23p19 antibodies | |
IL271697A (en) | Anti-cxcr3 antibodies | |
HK1217023A1 (en) | Novel antibodies | |
IL245190B (en) | Preparing antibodies from cho cell cultures for conjugation | |
SG11201509441QA (en) | Method for producing sheet-shaped cell culture | |
IL235042B (en) | Anti-fcrn antibodies | |
HK1210192A1 (en) | Anti-siglec-15 antibodies siglec-15 | |
EP2953892A4 (en) | Methods for fuel conversion | |
EP2895500A4 (en) | Antibody evolution immunogens | |
HK1221250A1 (en) | Structure for culturing cells | |
EP2970037A4 (en) | Methods for preparing alkylfurans | |
GB201420277D0 (en) | Cell culture system | |
PL2935330T3 (en) | Anti-notch3 antibodies | |
HK1202454A1 (en) | Anti-p-selectin antibody formulation -p- | |
GB201312226D0 (en) | Improved antibodies | |
EP2804876A4 (en) | Novel antibodies | |
EP2817395A4 (en) | Method for preparing biodiesel | |
SG11201507338PA (en) | Method for culturing cells | |
IL235188A0 (en) | Anti-pdgf-c antibodies | |
GB201308905D0 (en) | Cell culture | |
GB201306488D0 (en) | Cell culture |